MDSpire - MDSpire Home

MDSpire - MDSpire Home

Home About

Advertisement

What is MDSpire?

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

Learn More

Choose specialties Cardiology Dermatology Endocrinology Family Medicine Gastroenterology Hematology Internal Medicine Neurology ObGyn Oncology Ophthalmology Optometry Pediatrics Rheumatology Pulmonary Psychiatry Pathology Surgery Orthopedic Medicine Radiology Otolaryngology Infectious Disease Science

June 30, 2026

FDA Expands Pediatric Roflumilast Use

Kathryn Wighton
June 30, 2026
3 min

Summary
Takeaways
Quiz
Clinical Scorecard

Objective: To announce the FDA's approval of roflumilast cream 0.3% for the treatment of plaque psoriasis in pediatric patients aged 2 years and older. Approach

The FDA has approved roflumilast (ZORYVE) cream 0.3% for treating plaque psoriasis in pediatric patients aged 2 years and older.
Roflumilast was previously approved for adults and children aged 6 years and older at a lower 0.15% dose.
The approval was based on a study evaluating pharmacokinetics, safety, and efficacy in children aged 2 to 5 years.
Roflumilast cream is contraindicated in patients with moderate to severe liver impairment.
Common adverse reactions in trials included diarrhea, headache, insomnia, and application-site pain.

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

June 30, 2026

FDA Issues CRL for Oxylanthanum Carbonate

Kathryn Wighton
June 30, 2026
2 min

Summary
Insight Report
Poll

Objective: To report on the FDA's Complete Response Letter regarding Unicycive Therapeutics' New Drug Application for oxylanthanum carbonate. Approach: FDA Resp

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

June 30, 2026

HPV Chatbots Did Not Outperform Public Materials

Andrea Surnit
June 30, 2026
5 min

Summary
Insight Report
Quiz

Objective: To compare the effectiveness of brief conversations with a chatbot and public health materials on parents' intentions to vaccinate their children aga

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

June 30, 2026

How Does Social Media Influence Health Decisions?

Andrea Surnit
June 30, 2026
3 min

Summary
Quiz
Topic Commentary

Objective: To analyze the impact of social media on health-related decision-making among US adults. Approach: Survey Analysis: Investigators analyzed data from

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Get expert commentary that brings together trusted external perspectives to add deeper context and insight around a clinical topic.

Explore Commentary

June 30, 2026

Low Weight Linked to Severe Pediatric COVID

Andrea Surnit
June 30, 2026
4 min

Summary
Quiz
Clinical Scorecard

Objective: To investigate the association between nutritional status and clinical outcomes in pediatric patients with COVID-19 admitted to intensive care units.

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Medicine Maker

June 30, 2026

This Week's CGT News: World's First Solid Tumor CAR T Approved in China

June 30, 2026
6 min

Summary
Takeaways
Quiz
Poll
Clinical Scorecard

Objective: To report on the approval of the first CAR T therapy for solid tumors in China and related advancements in CAR T-cell therapy and gene therapy. Appro

China's National Medical Products Administration approved satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors.
Satricabtagene autoleucel targets Claudin18.2 and is approved for advanced gastric or gastroesophageal junction adenocarcinoma.
Approval is based on the phase 2 CT041-ST-01 trial, showing progression-free and overall survival benefits for satricabtagene autoleucel.
Wearable devices may help detect cytokine release syndrome earlier in CAR T-cell therapy patients, according to a pilot study.
A liver-targeted gene therapy showed promise in mice for treating arthrogryposis, renal dysfunction, and cholestasis syndrome.

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

The Medicine Maker

June 30, 2026

Reformulating the Future of Small Molecules

June 30, 2026
1 min

Summary
Insight Report
Quiz
Clinical Scorecard

Objective: To explore recent innovations and challenges in small molecule development, particularly in oral dosage forms. Approach: API Stability: Examines stre

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Analytical Scientist

June 30, 2026

Mass Spec Roundup: Hidden Origins and Cellular States

June 30, 2026
6 min

Summary
Takeaways
Insight Report
Quiz
Poll

Objective: To explore the origins of metabolites and cellular states using advanced mass spectrometry techniques. Approach: Microbiome Metabolites: Isotope trac

Mammalian cells can directly produce several circulating indole and phenol metabolites previously attributed to the gut microbiome.
Isotope tracing studies revealed that mammalian metabolism generates various aryl metabolites in physiologically relevant quantities.
A novel TurboID platform allows tracing of secreted proteins back to specific cell types, revealing changes across metabolic states.
Myc overexpression in cardiomyocytes shifts metabolic protein expression from fatty acid oxidation to glycolysis, indicating a pro-regenerative state.
MALDI imaging distinguishes macrophage phenotypes, showing that M1 macrophages synthesize more phospholipids than M2 cells.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

The Pathologist

June 30, 2026

Hantavirus at Sea: Cause for Concern?

Jessica Allerton
June 30, 2026
5 min

Summary
Insight Report
Poll
Topic Commentary

Objective: To provide insights from Mara Jana Broadhurst, microbiologist and infectious disease expert at the University of Nebraska Medical Center, on the rece

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Get expert commentary that brings together trusted external perspectives to add deeper context and insight around a clinical topic.

Explore Commentary

The Pathologist

June 30, 2026

How Diverse is the Pathology Workforce?

June 30, 2026
3 min

Summary
Takeaways
Insight Report
Quiz
Poll
Clinical Scorecard

Objective: To analyze the demographic diversity of the pathology workforce in the United States, focusing on gender and racial/ethnic representation among recen

Women constitute 53% of recently certified pathologists in the U.S., a significant increase from 27% among those certified before 2006.
Diversity in pathology remains uneven, with female representation at 39% in clinical pathology compared to 52% in anatomic pathology.
Racial and ethnic disparities persist, with 62% of active pathologists identifying as White and only 4% as Black or African American.
American Indian and Alaska Native individuals are underrepresented in pathology by approximately sevenfold compared to national population figures.
The study indicates that recruitment into pathology has become more diverse, but efforts are needed to support underrepresented groups in advancing their careers.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

The Medicine Maker

June 30, 2026

Why Early QC Planning Matters in Cell and Gene Therapy

Laurent Claisse
June 30, 2026
9 min

Summary
Takeaways
Insight Report
Poll
Clinical Scorecard

Objective: To highlight the importance of early quality control (QC) planning in the manufacturing of cell and gene therapies. Approach: Regulatory Expectations

Manufacturing or quality deficiencies accounted for 74% of Complete Response Letters issued by the FDA from 2020 to 2024.
Three high-profile cell and gene therapy programs faced delays or rejections in 2025 due to Chemistry, Manufacturing, and Control-related issues.
Early development decisions in gene therapy have significant downstream consequences, as emphasized by FDA guidance on CMC.
A cohesive QC strategy is essential, as it cannot be redesigned at each development stage without risking compliance and efficiency.
Geographical considerations in quality strategy are crucial, as operational habits can lead to documentation inconsistencies across regions.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

The Analytical Scientist

June 30, 2026

The Retina’s Lost Lipid Signal

June 30, 2026
2 min

Summary
Insight Report
Quiz

Objective: To identify lipid signals linked to retinal degeneration and assess the effects of restoring erucamide levels. Approach: Metabolomics Screening: Rese

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Medicine Maker

June 30, 2026

CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis

June 30, 2026
3 min

Summary
Insight Report
Poll

Objective: To evaluate the efficacy of engineered CAR T cells targeting TNF in a mouse model of rheumatoid arthritis. Approach: Engineering CAR T Cells: CD8-pos

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

The Ophthalmologist

June 30, 2026

Atsena Advances XLRS Gene Therapy

June 30, 2026
2 min

Summary
Insight Report
Quiz

Objective: To evaluate the efficacy of ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), in a Phase 3 pivotal trial. Approach: Trial

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Ophthalmologist

June 30, 2026

New Immune Target in Dry Eye

June 30, 2026
3 min

Summary
Insight Report
Quiz
Topic Commentary

Objective: To investigate the effects of the synthetic rexinoid compound NEt-3IB on ocular surface inflammation and goblet cell preservation in a mouse model of

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Get expert commentary that brings together trusted external perspectives to add deeper context and insight around a clinical topic.

Explore Commentary

Frontiers In Psychiatry

June 30, 2026

The effect of weather on unscheduled healthcare utilisation for mental health conditions in England, 2014–2022

Richard Elson
Julii Brainard
Natalia R. Jones
Alex J. Elliot
Iain R. Lake
June 30, 2026

Summary
Quiz
Clinical Scorecard

Objective: To examine associations between daily weather conditions and unscheduled mental health–related healthcare contacts in England using large-scale natio

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Frontiers In Oncology

June 30, 2026

SinglePass electrocautery device for closure of lung and mediastinal biopsy: a case series of 5 patients

Tust Techasith
Abhishek Jairam
Benjamin Park
Avinash Mesipam
Christopher Baker
Brian Cristiano
Thomas Velling
Trushar Patel
Behroz Oftadeh
Quan Dang
Lindsey Young
Vincent Nguyen
Kristen Raust
Matthew Roughley
Nathan Nguyen
Yurtizi Chavez
Alexander S. Misono
June 30, 2026

Summary
Takeaways
Insight Report
Quiz
Clinical Scorecard

Objective: To evaluate the safety, feasibility, and early outcomes of using the SinglePass electrocautery device for hemostasis and biopsy tract closure in lung

Percutaneous CT-guided biopsy is the preferred method for diagnosing thoracic lesions, offering high diagnostic yield with minimal invasiveness.
The SinglePass electrocautery device was used for hemostasis and biopsy tract closure in five cases of lung and mediastinal mass lesions.
All biopsy procedures using the SinglePass device were successful, with no complications reported within 30 days post-procedure.
Imaging confirmed the absence of pneumothorax and bleeding complications in all five patients after the procedures.
The SinglePass electrocautery device may help minimize pneumothorax and hemorrhagic complications during lung and mediastinal biopsies.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Frontiers In Oncology

June 30, 2026

Artificial intelligence for triple-negative breast cancer from imaging to multi-omics

Xing Peng
Xinyu Zhou
Xin Feng
Nimin Fang
Xiaoya Dong
Wanjing Hong
Tianli Li
Renxing Li
Mohammad Faidzul Nasrudin
June 30, 2026

Summary
Takeaways
Insight Report
Quiz
Clinical Scorecard

Objective: To synthesize previously published studies on AI applications in triple-negative breast cancer (TNBC) across various modalities and clinical tasks. A

Triple-negative breast cancer (TNBC) lacks robust biomarkers for diagnosis and treatment-response assessment due to its aggressive and heterogeneous nature.
Artificial intelligence (AI) is increasingly utilized in TNBC for analyzing imaging, digital pathology, and molecular data.
AI applications in TNBC include lesion segmentation, subtype classification, and prediction of treatment response and survival.
Current AI studies in TNBC face limitations such as small cohorts, inconsistent definitions, and inadequate external validation.
Future advancements in AI for TNBC will depend on multi-institutional data curation and reliable multimodal designs.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Advertisement

Advertisement

Advertisement

About
Privacy Policy

Follow Us

Author/Creator Name

[Credentials]

[Current title or role]

Affiliations: [Institution, organization]

Specialties: Oncology Hematology

View Full Profile

Contributions:

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

Show all